ISRCTN21576805 https://doi.org/10.1186/ISRCTN21576805

Phase II trial: ETH47-201

Submission date 23/05/2025	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 03/06/2025	**Overall study status** Deferred	
Last Edited 01/09/2026	**Condition category** Other	

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Contact information

Type(s)
Principal investigator

Contact name
Prof Onn Min Kon

Contact details
Imperial College Healthcare NHS Trust
South Wharf Road
London
United Kingdom
W2 1NY
+44 (0)203 312 1344
onn.kon@nhs.net

Type(s)
Scientific

Contact name
Dr Michael Edwards

Contact details
2 Royal College Street
London
United Kingdom

NW1 0NH
+44 (0)20 7554 5855
info@virtus-rr.com

Type(s)
Public

Contact name
Ms Tika Endeladze

Contact details
2 Royal College Street
London
United Kingdom
NW1 0NH
+44 (0)20 7554 5855
info@virtus-rr.com

Additional identifiers

Integrated Research Application System (IRAS)
1011224

Protocol serial number
ETH47-201

Study information

Scientific Title
Phase II trial: ETH47-201

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 14/02/2025, Wales 3 REC (Wales Research Ethics Committee 3, Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941107; Wales.REC3@wales.nhs.uk), ref: 25/WA/0013

Primary study design
Interventional

Study design
Phase II double-blind randomized placebo-controlled study in 50 volunteers with asthma

Study type(s)
Treatment

Health condition(s) or problem(s) studied
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Intervention Type
Drug

Phase
Phase II

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Key secondary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Completion date
01/09/2026

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Total final enrolment
50

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Date of first enrolment
09/06/2025

Date of final enrolment
20/07/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Imperial College Respiratory Research Unit
Imperial College Healthcare NHS Trust
Mint Wing
South Wharf Road
St Mary's Hospital
London
England
W2 1NY

Study participating centre
Medicines Evaluation Unit Limited
The Langley Building
Southmoor Road
Wythenshawe
Manchester
England
M23 9QZ

Sponsor information

Organisation
Ethris GmbH

Funder(s)

Funder type
Industry

Funder Name
Ethris GmbH

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available